Beyond mesothelin, additional targets such as prostate stem cell antigen (PSCA), carcinoembryonic antigen (CEA), mucin-1 (MUC1), and CD24 have shown efficacy in preclinical models of pancreatic cancer. This evidence concerns the gene MUC1 and familial pancreatic carcinoma.